Business news

    Radiopharm Theranostics (ASX:RAD) secures $70M funding from international and Australian investors

    Article Image

    Radiopharm Theranostics secured commitments to raise approximately $70 million through a strategic placement involving international and Australian institutional investors.

    The placement includes an investment from Lantheus Holdings and specialist US healthcare investors.

    Lantheus has committed an initial $7.5 million investment at 5 cents per share. Under similar terms, Lantheus can invest another $7.5 million within the next six months.

    Radiopharm has transferred rights to two preclinical assets to Lantheus for $3 million in a separate agreement.

    Proceeds from the placement will be used for drug manufacturing, clinical trials, general working capital, and the costs associated with the capital raising.

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa